An-Najah News - A clinical trial in France begins with the transfer of plasma of people who have recovered from the corona virus to “patients in an acute stage of the disease,” as what the institutions responsible for the matter have announced.

These institutions, including the National Institute for Medical Research (Inserm), said: “This experiment is based on transferring plasma from patients who have recovered from COVID-19 and containing anti-virus antibodies, to patients suffering from the virus in an attempt to provide them with this immunity.”

“The plasma of people who have recovered from corona virus contains these antibodies, and it may help patients who are in an acute stage of the disease fight the virus," they said.

Specific samples will be taken in the Paris region and eastern France, from about 200 people who recovered for at least 14 days.

The clinical trial will be done on 60 patients in Paris hospitals, "half of whom will get plasma", with a first evaluation conducted one to 3 weeks after the start of the trial.

The efficacy of plasma, a part of the liquid blood in which antibodies are concentrated after a disease, has been demonstrated in those recovering  in small-scale studies against other infectious diseases such as “Ebola” and “SARS”.